-
Je něco špatně v tomto záznamu ?
Clinical testing of antiretroviral drugs as future prevention against vaginal and rectal transmission of HIV infection - a review of currently available results
J. Vysloužil, K. Kubová, VN. Tkadlečková, D. Vetchý,
Jazyk angličtina Země Chorvatsko
Typ dokumentu časopisecké články, přehledy
NLK
Directory of Open Access Journals
od 2007
Free Medical Journals
od 2003
ProQuest Central
od 2007-03-01
Open Access Digital Library
od 2007-01-01
Open Access Digital Library
od 2007-02-28
Health & Medicine (ProQuest)
od 2007-03-01
Sciendo
od 2007-02-28
ROAD: Directory of Open Access Scholarly Resources
od 1997
PubMed
31259738
DOI
10.2478/acph-2019-0030
Knihovny.cz E-zdroje
- MeSH
- antikoncepční prostředky ženské virologie MeSH
- antiretrovirové látky terapeutické užití MeSH
- HIV infekce farmakoterapie MeSH
- klinické zkoušky, fáze III jako téma MeSH
- lidé MeSH
- rektum virologie MeSH
- vagina virologie MeSH
- Check Tag
- lidé MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
The original purpose of vaginally applied microbicides was to slow down the HIV epidemic among the population until an effective vaccination was developed. Nowadays, antiretrovirals applied in the form of gels or vaginal rings are considered most prominent in this field and are tested via vaginal or, rarely, rectal applications in numerous clinical studies (9 different antiretroviral drugs in 33 clinical studies, especially in Africa). Only tenofovir (1 % gel) and dapivirine (25 mg in vaginal ring) progressed into the phase III clinical testing. Their efficiency depended on the user´s strict adherence to the application regimen (for tenofovir 54 %, for dapivirine 61 % in participants over 25 years of age). Despite this, they are expected to be important and effective tools of preventive medicine in the near future. This review summarizes the results obtained during long-term clinical testing (2005-2018) of antiretroviral drugs against vaginal and rectal transmission of HIV infection.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19044707
- 003
- CZ-PrNML
- 005
- 20200113081218.0
- 007
- ta
- 008
- 200109s2019 ci f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.2478/acph-2019-0030 $2 doi
- 035 __
- $a (PubMed)31259738
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ci
- 100 1_
- $a Vysloužil, Jakub $u Department of Pharmaceutics, Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences Brno, Brno, Czech Republic.
- 245 10
- $a Clinical testing of antiretroviral drugs as future prevention against vaginal and rectal transmission of HIV infection - a review of currently available results / $c J. Vysloužil, K. Kubová, VN. Tkadlečková, D. Vetchý,
- 520 9_
- $a The original purpose of vaginally applied microbicides was to slow down the HIV epidemic among the population until an effective vaccination was developed. Nowadays, antiretrovirals applied in the form of gels or vaginal rings are considered most prominent in this field and are tested via vaginal or, rarely, rectal applications in numerous clinical studies (9 different antiretroviral drugs in 33 clinical studies, especially in Africa). Only tenofovir (1 % gel) and dapivirine (25 mg in vaginal ring) progressed into the phase III clinical testing. Their efficiency depended on the user´s strict adherence to the application regimen (for tenofovir 54 %, for dapivirine 61 % in participants over 25 years of age). Despite this, they are expected to be important and effective tools of preventive medicine in the near future. This review summarizes the results obtained during long-term clinical testing (2005-2018) of antiretroviral drugs against vaginal and rectal transmission of HIV infection.
- 650 _2
- $a antiretrovirové látky $x terapeutické užití $7 D044966
- 650 _2
- $a klinické zkoušky, fáze III jako téma $7 D017326
- 650 _2
- $a antikoncepční prostředky ženské $x virologie $7 D003274
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a HIV infekce $x farmakoterapie $7 D015658
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a rektum $x virologie $7 D012007
- 650 _2
- $a vagina $x virologie $7 D014621
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Kubová, Kateřina $u Department of Pharmaceutics, Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences Brno, Brno, Czech Republic.
- 700 1_
- $a Tkadlečková, Veronika Nováková $u Department of Pharmaceutics, Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences Brno, Brno, Czech Republic.
- 700 1_
- $a Vetchý, David $u Department of Pharmaceutics, Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences Brno, Brno, Czech Republic.
- 773 0_
- $w MED00000116 $t Acta pharmaceutica (Zagreb, Croatia) $x 1846-9558 $g Roč. 69, č. 3 (2019), s. 297-319
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/31259738 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20200109 $b ABA008
- 991 __
- $a 20200113081550 $b ABA008
- 999 __
- $a ok $b bmc $g 1482976 $s 1083380
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 69 $c 3 $d 297-319 $e 2019Sep01 $i 1846-9558 $m Acta pharmaceutica $n Acta Pharm $x MED00000116
- LZP __
- $a Pubmed-20200109